Stage IV Mycosis Fungoides/Sezary Syndrome (DBCOND0028720)

Identifiers

Synonyms
Mycosis fungoides/Sezary syndrome stage IV / Stage 4 Mycosis Fungoides/Sezary Syndrome / Cutaneous T-cell lymphoma stage IV

Associated Data

Indicated Drugs and Targets
Not Available
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT00489203
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancersupportive_care2completed
NCT00293345
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphomatreatment1completed
NCT01129193
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphomatreatment1completed
NCT00354185
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomatreatment1terminated
NCT00025415
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunctiontreatment1completed
NCT00003970
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphomatreatment1completed
NCT01158274
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumorstreatment1completed
NCT00098891
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomastreatment1completed
NCT01199562
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantNot AvailableNot Availablecompleted
NCT00049504
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancertreatment2completed
NCT00040846
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignanciestreatment2completed
NCT00052377
Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoidestreatment1 / 2terminated
NCT01044745
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancertreatment2terminated
NCT00096005
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomastreatment1terminated
NCT00499811
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunctiontreatment1completed
NCT00089271
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomastreatment1completed
NCT00769288
FAU in Treating Patients With Advanced Solid Tumors or LymphomaNo drug interventionstreatment1completed
NCT00348985
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomastreatment1completed
NCT00601718
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphomatreatment1 / 2completed
NCT00004241
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcomatreatment1completed
NCT01273766
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignanciessupportive_care2completed
NCT01053494
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerNo drug interventionssupportive_careNot Availablecompleted
NCT00005080
506U78 in Treating Patients With Lymphomatreatment2completed
NCT00077155
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphomatreatment1completed